K Mitsuzuka1, S Narita2, T Koie3, Y Kaiho1, N Tsuchiya2, T Yoneyama3, N Kakoi4, S Kawamura4, T Tochigi4, C Ohyama2, T Habuchi3, Y Arai1. 1. 1] Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan [2] Michinoku Japan Urological Cancer Study Group, Sendai, Japan. 2. 1] Michinoku Japan Urological Cancer Study Group, Sendai, Japan [2] Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. 3. 1] Michinoku Japan Urological Cancer Study Group, Sendai, Japan [2] Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. 4. 1] Michinoku Japan Urological Cancer Study Group, Sendai, Japan [2] Department of Urology, Miyagi Cancer Center, Natori, Japan.
Abstract
BACKGROUND: The significance of lymphovascular invasion (LVI) remains controversial, and the association of LVI with biochemical relapse was investigated in men treated with radical prostatectomy according to pathological results. METHODS: Data from 1268 patients undergoing radical prostatectomy between 2000 and 2009 were retrospectively reviewed. Clinicopathological variables were compared between LVI-negative and LVI-positive patients. Multivariate analyses by Cox proportional hazard model and Kaplan-Meier method were performed to identify risk factors for biochemical relapse in all patients, patients with pT2N0 and pT2N0 negative resection margin (RM). RESULTS: LVI information was available in 1160 cases, and LVI was seen in 121 cases (10.4%). Clinicopathological variables were significantly worse in LVI-positive patients than in LVI-negative patients. On multivariate analyses, PSA⩾10 ng ml(-1), pathological Gleason score ⩾8, pathological T stage ⩾3, lymph node metastasis, positive RM and LVI were independent predictors for biochemical relapse in all patients. In patients with pT2N0, PSA⩾10 ng ml(-1), pathological Gleason score ⩾8, positive RM and LVI were independent predictors for biochemical relapse. In patients with pT2N0 negative RM, LVI and pathological Gleason score ⩾8 were independent predictors for biochemical relapse (LVI; hazard ratio 3.809, 95% confidence interval 1.900-7.635, P-value<0.001, Gleason score ⩾8; hazard ratio 2.189, 95% confidence interval 1.199-3.999, P-value=0.011). With a median follow-up of 50 months, 5-year biochemical relapse-free survival in patients with pT2N0 negative RM was 95.7% in those with negative LVI in comparison to 85.3% in those with positive LVI (P<0.001, log rank). CONCLUSIONS: LVI was consistently a significant predictor for biochemical relapse after radical prostatectomy in not only all patients but also in patients with pT2N0 and pT2N0 negative RM. These results strongly support the significance of LVI as a predictor for biochemical relapse.
BACKGROUND: The significance of lymphovascular invasion (LVI) remains controversial, and the association of LVI with biochemical relapse was investigated in men treated with radical prostatectomy according to pathological results. METHODS: Data from 1268 patients undergoing radical prostatectomy between 2000 and 2009 were retrospectively reviewed. Clinicopathological variables were compared between LVI-negative and LVI-positive patients. Multivariate analyses by Cox proportional hazard model and Kaplan-Meier method were performed to identify risk factors for biochemical relapse in all patients, patients with pT2N0 and pT2N0 negative resection margin (RM). RESULTS: LVI information was available in 1160 cases, and LVI was seen in 121 cases (10.4%). Clinicopathological variables were significantly worse in LVI-positive patients than in LVI-negative patients. On multivariate analyses, PSA⩾10 ng ml(-1), pathological Gleason score ⩾8, pathological T stage ⩾3, lymph node metastasis, positive RM and LVI were independent predictors for biochemical relapse in all patients. In patients with pT2N0, PSA⩾10 ng ml(-1), pathological Gleason score ⩾8, positive RM and LVI were independent predictors for biochemical relapse. In patients with pT2N0 negative RM, LVI and pathological Gleason score ⩾8 were independent predictors for biochemical relapse (LVI; hazard ratio 3.809, 95% confidence interval 1.900-7.635, P-value<0.001, Gleason score ⩾8; hazard ratio 2.189, 95% confidence interval 1.199-3.999, P-value=0.011). With a median follow-up of 50 months, 5-year biochemical relapse-free survival in patients with pT2N0 negative RM was 95.7% in those with negative LVI in comparison to 85.3% in those with positive LVI (P<0.001, log rank). CONCLUSIONS: LVI was consistently a significant predictor for biochemical relapse after radical prostatectomy in not only all patients but also in patients with pT2N0 and pT2N0 negative RM. These results strongly support the significance of LVI as a predictor for biochemical relapse.
Authors: Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump Journal: Lancet Oncol Date: 2006-06 Impact factor: 41.316
Authors: Kristin A Higgins; Junzo P Chino; Neal Ready; Thomas A D'Amico; Mark F Berry; Thomas Sporn; Jessamy Boyd; Chris R Kelsey Journal: J Thorac Oncol Date: 2012-07 Impact factor: 15.609
Authors: Fadia J A Gujam; James J Going; Joanne Edwards; Zahra M A Mohammed; Donald C McMillan Journal: Crit Rev Oncol Hematol Date: 2013-09-12 Impact factor: 6.312
Authors: David S Yee; Shahrokh F Shariat; William T Lowrance; Alexandra C Maschino; Caroline J Savage; Angel M Cronin; Peter T Scardino; James A Eastham Journal: BJU Int Date: 2010-11-02 Impact factor: 5.588
Authors: James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho Journal: J Natl Compr Canc Netw Date: 2014-05 Impact factor: 11.908
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Derya Tilki; Shahrokh F Shariat; Yair Lotan; Michael Rink; Pierre I Karakiewicz; Mark P Schoenberg; Seth P Lerner; Guru Sonpavde; Arthur I Sagalowsky; Amit Gupta Journal: BJU Int Date: 2012-11-26 Impact factor: 5.588
Authors: Yong Jin Kang; Hyun-Soo Kim; Won Sik Jang; Jong Kyou Kwon; Cheol Yong Yoon; Joo Yong Lee; Kang Su Cho; Won Sik Ham; Young Deuk Choi Journal: BMC Cancer Date: 2017-05-08 Impact factor: 4.430